INMInMed Pharmaceuticals Inc.
The schedule
- Thu15Oct
Over the next 12 months, InMed Pharmaceuticals Inc. may pursue a strategic partnership or out-licensing transaction to validate its cannabinoid platform and secure non-dilutive funding. From a base price of $0.55, a partner with meaningful upfront cash, shared development costs, or regional commercialization rights could rerate the stock toward $0.90, while failure to secure such a deal or a weakly structured agreement could disappoint investors and leave shares hovering closer to $0.45.
- Sat14Nov
- Thu19Nov
In the second half of 2026, InMed Pharmaceuticals Inc. is likely to provide a consolidated update on its cannabinoid-based therapeutic pipeline at scientific or investor meetings. From a base price of $0.50, constructive data on safety or early efficacy and a clearer regulatory pathway could lift the stock toward $0.70, while any signal of delays, underwhelming data, or deprioritization of key programs could see shares slide toward $0.70 as investors question long-term value.
- Mon30Nov
With InMed Pharmaceuticals Inc. trading under $1.00 for a prolonged period, the risk of exchange listing pressure and a potential reverse split increases into late 2026. If the company maintains compliance or executes a reverse split alongside improved fundamentals and communication, the stock could stabilize around $0.95 on a pre-event equivalent basis, while a reverse split perceived as purely cosmetic or the threat of delisting could drag the effective price down toward $0.95 in pre-split terms.
- Wed10Feb
Past
- Sat15Aug
Actual outcome: Bull · $1.38 at outcome
No dilutive equity financing or material corporate updates were announced around the event date. While the stock experienced a 6.1% pullback during the observation window, it sustained levels well above the $0.90 bull target, closing at $1.38, as the anticipated risk of a near-term capital raise did not materialize.
Given InMed Pharmaceuticals Inc.'s modest revenue base, persistent net losses, and limited cash, a follow-on equity financing or ATM usage over the next 12 months is a material risk. If a raise occurs around mid-2026 once the stock has potentially recovered toward $0.90, a well-structured deal with quality investors and clear use of proceeds could support a move toward $0.90 by de-risking the runway, but a deeply discounted or repeated capital raise would likely drag the stock down toward $0.90.
